Full-Time
Clinical Research Nurse
WEP Clinical
201-500 employees
Specialist services for early access medicines
Compensation Overview
$50 - $55/hr
Portland, ME, USA
In Person
Travel time is compensated; drive time estimated at 1–2 hours from location.
 Medical, Clinical & Veterinary (1) |
|---|
- Relevant Nurse Licensure
- CH-GCP Certificate
- Graduate from an accredited Bachelor of Science in Nursing or Associate Degree in Nursing or Nursing Diploma program
- Minimum 2 years’ post qualification acute care experience
- BLS certification required
- Experience and knowledge of working in clinical research trials with ICH-Good Clinical Practice Certification - (training can be provided)
- Good basic IT skills, utilizing mobile devices and Microsoft systems
- Trained in Handling and Transport of Hazardous Substances (training can be provided)
- A flexible schedule is essential
- Unencumbered driver’s license, reliable car
- Deliver competent, high-quality nursing care to study patients in their homes.
- Accountable for the competent and confident delivery of high-quality clinical care to patients/participants. Ensure compliance with each study’s protocol by providing thorough review and documentation at each subject study visit.
- Administer investigational medications/products as needed; Perform patient assessments to determine presence of side effects; notify Principal Investigator of findings/issues.
- Perform medical tests as outlined in protocol, including, but not limited to: vital signs, specimen collection, electrocardiograms; Process specimens and ship specimens per protocol.
- Provide patient education and medical information to study patients to ensure understanding of proper medication dosage, administration, and disease treatment.
- Responsible for adherence to clinical research policies to ensure ethical conduct and protect vulnerable populations.
- Communicate effectively, promoting open and trusting relationships.
- Clinical Research experience preferred
- ICH-GCP Certification (training can be provided)
WEP Clinical provides access to unlicensed or scarce medicines through Expanded Access Programs (EAP) and Managed Access Programs (MAP) for hospitals and physicians in over 60 countries. It uses a global sourcing network and handles import authorizations to obtain medicines that aren’t commercially available or are in short supply. A team of country managers and in-house pharmacists with local language skills coordinates and ships medications to healthcare providers. Revenue comes from service fees for managing access programs and sourcing medicines, with the goal of getting necessary treatments to patients quickly.
Company Size
201-500
Company Stage
N/A
Total Funding
N/A
Headquarters
Morrisville, North Carolina
Founded
2008
Simplify's Take
What believers are saying
- Siron integration expands CRO services in orphan diseases and Europe.
- EU NPP regulations enable revenue from post-approval drug supplies.
- Partnerships with Y-mAbs and TaiMed drive steady program revenues.
What critics are saying
- Siron acquisition integration fails, eroding efficiency in 6-12 months.
- EMA enforces stricter NPP import rules, cutting EU revenue in 12-24 months.
- Parexel poaches biotech clients, shrinking rare disease market share immediately.
What makes WEP Clinical unique
- WEP Clinical manages EAPs and MAPs for unlicensed medicines across 60 countries.
- In-house pharmacists and country managers secure import authorizations globally.
- Acquired Siron Clinical on January 5, 2026, adding Phase I-IV trial expertise.
Help us improve and share your feedback! Did you find this helpful?
Your Connections
People at WEP Clinical who can refer or advise you
Benefits
Health Insurance
Disability Insurance
Life Insurance
Parental Leave
Flexible Work Hours
Training Programs
Company News
WEP Clinical acquires Siron Clinical. WEP Clinical acquires Netherlands-based CRO Siron Clinical, expanding global Phase I - IV trial delivery capabilities. Morrisville, NC, USA & London, UK - [January 05, 2026] - WEP Clinical (WEP), a full-service contract research organization (CRO), today announced the acquisition of Siron Clinical (Siron), a Netherlands-based European CRO specializing in flexible, high-quality clinical operations for biotech companies. The acquisition expands WEP's global footprint and strengthens its ability to deliver end-to-end Phase I - IV clinical trial solutions across complex, rare, and specialized therapeutic areas. Founded in 2000, Siron is headquartered in the Netherlands, with additional offices in Belgium and Germany, and clinical research professionals based across Europe and the Middle East. The company specializes in clinical operations, including project management, clinical monitoring, quality assurance, and regulatory submissions. Siron has supported more than 120 studies and is recognized for its strong track record in orphan diseases, pediatric research, and medical device trials. "This acquisition represents a significant milestone in the evolution of our CRO services. By combining WEP's global infrastructure with Siron Clinical's deep operational expertise in complex and niche indications, we can offer sponsors seamless support from early-phase development through post-approval research. Our shared culture, values, and commitment to execution excellence make this an ideal strategic fit, and we look forward to accelerating innovation and impact together." "Joining WEP gives our clients access to expanded services and global reach, while preserving the flexible, hands-on approach they value. We share WEP's commitment to quality, transparency, and patient-focused delivery, and together we will provide a more robust and scalable solution for biotech sponsors worldwide." Siron will be integrated into WEP's Clinical Trials division, enhancing WEP's existing capabilities across trial design, regulatory strategy, start-up, patient recruitment, study execution, and close-out. Clients will benefit from a larger pool of experienced CRAs, project managers, and operational leaders, alongside WEP's broader treatment access and commercialization offerings. WEP Clinical is a global Clinical Research Organization with expertise in designing, managing, and executing clinical trials across multiple therapeutic areas. With a strong focus on proactive project management, scientific integrity, regulatory compliance, and patient-centric execution, WEP supports pharmaceutical and biotech companies in bringing life-changing therapies to market efficiently and safely. Siron Clinical is a European CRO providing flexible and scalable clinical operations expertise for biotech organizations. With more than two decades of experience executing complex clinical trials, Siron delivers localized insight, hands-on support, and adaptive solutions across the clinical development journey.
WEP Clinical has partnered with Plusultra pharma to supply HYFTOR(R) to patients in EU/EEA countries (with the exception of Germany).
WEP Clinical LTD (WEP), a specialist services company that works with pharmaceutical companies to help patients and physicians gain access to medicines when no other treatment options are available, has partnered with TaiMed Biologics to launch a Named Patient Program (NPP) for TROGARZO®, an IV treatment administered every two weeks for patients with muti-drug resistant HIV disease.
Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that it has entered into a distribution agreement with WEP Clinical Ltd. (“WEP”) in connection with an early access program for DANYELZA (naxitamab-gqgk) 40mg/10mL Injection in Europe.
Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that it has entered into a distribution agreement with WEP Clinical Ltd. (“WEP”) in connection with an early access program for DANYELZA (naxitamab-gqgk) 40mg/10mL Injection in Europe.